In breast cancer, IGFBP7 treatment inhibited cell growth and induced apoptosis and senescence, in vitro and in vivo, only in cell lines that were tested negative for HER2/neu, estrogen and progesterone [72]. Here, ERBB2 is linked to breast carcinoma.